| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1001455608 |
| P356 | DOI | 10.1038/222385A0 |
| P953 | full work available at URL | http://www.nature.com/articles/222385a0 |
| http://www.nature.com/articles/222385a0.pdf | ||
| P698 | PubMed publication ID | 5782119 |
| P5875 | ResearchGate publication ID | 17404231 |
| P2093 | author name string | B. Rosenberg | |
| J. E. Trosko | |||
| VanCamp L | |||
| L. VanCamp | |||
| V. H. Mansour | |||
| P2860 | cites work | Effectiveness of nitrogen mustards in retarding the growth of sarcoma 180 with reference to route of administration, age of tumors, food intake, and weight loss of the mice | Q47449659 |
| INHIBITION OF CELL DIVISION IN ESCHERICHIA COLI BY ELECTROLYSIS PRODUCTS FROM A PLATINUM ELECTRODE | Q28202030 | ||
| P433 | issue | 5191 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | platinum | Q880 |
| P304 | page(s) | 385-386 | |
| P577 | publication date | 1969-04-01 | |
| P1433 | published in | Nature | Q180445 |
| P1476 | title | Platinum compounds: a new class of potent antitumour agents | |
| Platinum Compounds: a New Class of Potent Antitumour Agents | |||
| P478 | volume | 222 |
| Q43819170 | 3-D QSAR studies on new dibenzyltin(IV) anticancer agents by comparative molecular field analysis (CoMFA). |
| Q38782365 | 3-octadecylcarbamoylacrylic acid-cisplatin nanocomplexes for the development of novel liposome formulation |
| Q67290762 | A Circular Dichroism Study of DNA . Platinum Complexes. Differentiation between Monofunctional. cis-Bidentate and trans-Bidentate Platinum Fixation on a Series of DNAs |
| Q91761770 | A Comprehensive Review on the Synthesis, Characterization, and Biomedical Application of Platinum Nanoparticles |
| Q92632504 | A New Look into the Mode of Action of Metal-Based Anticancer Drugs |
| Q38953565 | A TrxR inhibiting gold(I) NHC complex induces apoptosis through ASK1-p38-MAPK signaling in pancreatic cancer cells. |
| Q28546961 | A better experimental method to detect the sensitivity of cancer cells to anticancer drugs after adenovirus-mediated introduction of two kinds of p53 in vivo |
| Q39570737 | A bifunctional organometallic ruthenium drug with multiple modes of inducing apoptosis |
| Q54486007 | A cDNA microarray analysis identifies 52 genes associated with cis-diamminedichloroplatinum susceptibility in head and neck squamous cell carcinoma cell lines. |
| Q51140866 | A comprehensive biological insight of trinuclear copper(II)-tin(IV) chemotherapeutic anticancer drug entity: in vitro cytotoxicity and in vivo systemic toxicity studies. |
| Q43411545 | A core cross-linked polymeric micellar platium(IV) prodrug with enhanced anticancer efficiency |
| Q40202099 | A crystalline platinum blue: its molecular structure, chemical reactivity, and possible relevance to the mode of action of antitumor platinum drugs |
| Q40774280 | A crystallographic study of metal-binding to yeast phenylalanine transfer RNA |
| Q58921543 | A dinuclear cyclometalated gold(iii)–phosphine complex targeting thioredoxin reductase inhibits hepatocellular carcinoma in vivo |
| Q44320923 | A fluorescent probe for investigating the activation of anticancer platinum(IV) prodrugs based on the cisplatin scaffold. |
| Q40162812 | A glucose derivative as natural alternative to the cyclohexane-1,2-diamine ligand in the anticancer drug oxaliplatin? |
| Q45260669 | A kinetic and mechanistic study into the substitution behaviour of platinum(II) polypyridyl complexes with a series of azole ligands |
| Q54066529 | A molecular cytogenetic approach to studying platinum resistance. |
| Q36785185 | A new anticancer platinum compound, (-)-(R)-2-aminomethyl-pyrrolidine(1,1-cyclobutanedicarboxylato) platinum(II): DNA interstrand crosslinking, repair and lethal effects in normal human, Fanconi's anaemia and xeroderma pigmentosum cells |
| Q42043312 | A new, semi-automated system for the micro-scale synthesis of [195mPt]cisplatin suitable for clinical studies |
| Q46474564 | A note from history: Landmarks in history of cancer, Part 6. |
| Q28484947 | A novel and selective poly (ADP-ribose) polymerase inhibitor ameliorates chemotherapy-induced painful neuropathy |
| Q38984020 | A novel manganese complex LMnAc selectively kills cancer cells by induction of ROS-triggered and mitochondrial-mediated cell death |
| Q86044072 | A novel ruthenium(II)-polypyridyl complex inhibits cell proliferation and induces cell apoptosis by impairing DNA damage repair |
| Q41912667 | A pH responsive complexation-based drug delivery system for oxaliplatin |
| Q33494306 | A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days. |
| Q39214856 | A polymer-(tandem drugs) conjugate for enhanced cancer treatment |
| Q39173607 | A potential rhodium cancer therapy: studies of a cytotoxic organorhodium(I) complex that binds DNA. |
| Q35868560 | A review of selected anti-tumour therapeutic agents and reasons for multidrug resistance occurrence |
| Q42464258 | A semiquantitative analysis of the effects of cisplatin on the rat stria vascularis |
| Q37905280 | A strategy for the development of two clinically active cisplatin analogs: CBDCA and CHIP. |
| Q38792102 | A survey of the mechanisms of action of anticancer transition metal complexes |
| Q39557153 | A tetrazolato-bridged dinuclear platinum(II) complex exhibits markedly high in vivo antitumor activity against pancreatic cancer. |
| Q78179609 | Absorbed doses to patients from 191Pt-, 193mPt- and 195mPt-cisplatin |
| Q105245784 | Aciculatin, a novel flavone-C-glycoside with DNA binding activity from chrysopogon aciculatis |
| Q90859353 | Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer |
| Q46874152 | Activity of two platinum-linked phosphonic acids against autochthonous rat colorectal cancer as well as in two human colon-cancer cell lines |
| Q38412888 | Acute and sub-chronic toxicity of four cytostatic drugs in zebrafish. |
| Q64033563 | Adduct formation of cis-(NH3)2PtX2 (X = Cl−, I−) with formamides and the crystal structures of cis-(NH3)2PtCl2·(CH3)2NCHO. Application for the purification of the antitumor agent cisplatin |
| Q33385228 | Adenoviral-mediated pHyde gene transfer and cisplatin additively inhibit human prostate cancer growth by enhancing apoptosis |
| Q28072577 | Advances and Challenges in Viability Detection of Foodborne Pathogens |
| Q39653970 | Advances in platinum cancer chemotherapy. Advances in the design of cisplatin analogues |
| Q47274509 | Aerobic reactions of antitumor active dirhodium(II) tetraacetate Rh2(CH3COO)4 with glutathione |
| Q36396542 | Altered DNA binding and amplification of human breast cancer suppressor gene BRCA1 induced by a novel antitumor compound, [Ru(η(6)-p-phenylethacrynate)Cl(2)(pta)]. |
| Q46088554 | An experimental and theoretical investigation into the hydrolysis of dichloro(ethylenediamine)platinum(II) via electrospray mass spectrometry and density functional theory |
| Q28080615 | An integrated view of cisplatin-induced nephrotoxicity and ototoxicity |
| Q38975452 | An integrative view of cisplatin-induced renal and cardiac toxicities: Molecular mechanisms, current treatment challenges and potential protective measures |
| Q30855124 | An unusual ligand coordination gives rise to a new family of rhodium metalloinsertors with improved selectivity and potency |
| Q92586137 | Analysing central metabolism in ultra-high resolution: At the crossroads of carbon and nitrogen |
| Q57552230 | Analysis of the Current Situation of Antitumor Drug Use in China |
| Q39738527 | Anionic linear-globular dendrimer-cis-platinum (II) conjugates promote cytotoxicity in vitro against different cancer cell lines |
| Q28344764 | Anti-Candida activity of a new platinum derivative |
| Q40796522 | Anti-HIV and cytotoxic activities of Ru(II)/Ru(III) polypyridyl complexes containing 2,6-(2'-benzimidazolyl)-pyridine/chalcone as co-ligand |
| Q28553698 | Anti-Invasive and Anti-Proliferative Synergism between Docetaxel and a Polynuclear Pd-Spermine Agent |
| Q38203819 | Anti-cancer palladium complexes: a focus on PdX2L2, palladacycles and related complexes |
| Q36292954 | Anti-proliferative activity and mechanism of action of titanocene dichloride |
| Q39961719 | Anti-tumour activity of heavy transition metal complexes against hepatoma cells |
| Q59101621 | Anticancer Activities of Mononuclear Ruthenium(II) Coordination Complexes |
| Q47827072 | Anticancer Activity of Copper Complex of (4R)-(-)-2-Thioxo-4-thiazolidinecarboxylic Acid and 3-Rhodaninepropionic Acid on Prostate and Breast Cancer Cells by Fluorescent Microscopic Imaging. |
| Q90334551 | Anticancer Ruthenium(III) Complexes and Ru(III)-Containing Nanoformulations: An Update on the Mechanism of Action and Biological Activity |
| Q39732972 | Anticancer activity of a chelating nitrogen mustard bearing tetrachloridoplatinum(iv) complex: better stability yet equipotent to the Pt(ii) analogue. |
| Q37833099 | Anticancer activity of metal complexes: involvement of redox processes |
| Q30515979 | Anticancer activity of methyl-substituted oxaliplatin analogs |
| Q39387194 | Anticancer activity of silver-N-heterocyclic carbene complexes: caspase-independent induction of apoptosis via mitochondrial apoptosis-inducing factor (AIF). |
| Q36639291 | Anticancer drug discovery and pharmaceutical chemistry: a history |
| Q39029785 | Anticancer potential of (pentamethylcyclopentadienyl)chloridoiridium(III) complexes bearing κP and κP,κS-coordinated Ph2 PCH2 CH2 CH2 S(O)x Ph (x=0-2) ligands. |
| Q67240403 | Antileukaemic and Nephrotoxic Properties of Platinum Compounds |
| Q41774809 | Antileukemic Efficacy of Monomeric Manganese-Based Metal Complex on KG-1A and K562 Cell Lines |
| Q51551365 | Antileukemic activity and cellular effects of rhodium(III) crown thiaether complexes. |
| Q39496661 | Antineoplastic drugs: clinical pharmacology and therapeutic use. |
| Q99632123 | Antioxidant effect of acetyl-l-carnitine against cisplatin-induced cardiotoxicity |
| Q59229108 | Antiproliferative Activity of PtII Complexes with Carboxylated Phosphanes in Chelated or Ring-Opened Forms |
| Q39619138 | Antiproliferative activity of chelating N,O- and N,N-ruthenium(II) arene functionalised poly(propyleneimine) dendrimer scaffolds |
| Q45159072 | Antitumor activity and cellular accumulation of a new platinum complex, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)platinum( II) monohydrate, in cisplatin-sensitive and -resistant murine P388 leukemia cells |
| Q37481696 | Antitumor activity and toxicity of salts of inorganic group 3a metals: aluminum, gallium, indium, and thallium |
| Q69491820 | Antitumor activity of imidazolium-bisimidazole-tetrachlororuthenate (III). A representative of a new class of inorganic antitumor agents |
| Q54098993 | Antitumour activity of oxaliplatin in neuroblastoma cell lines. |
| Q43918428 | Antitumour and toxic effects on Wistar rats of two new platinum complexes |
| Q34632511 | Anvirzel™ in combination with cisplatin in breast, colon, lung, prostate, melanoma and pancreatic cancer cell lines |
| Q40280745 | Apoptosis of human breast carcinoma cells in the presence of cis-platin and L-/D-PPMP: IV. Modulation of replication complexes and glycolipid: Glycosyltransferases |
| Q46941824 | Apoptosis-inducing ability of silver(I) cyanide-phosphines useful for anti-cancer studies |
| Q39706669 | Arene ruthenium complexes as anticancer agents |
| Q57007836 | Assessment of exposure to platinum-group metals in urban children |
| Q43247159 | Astrocyte elevated gene-1 regulates osteosarcoma cell invasion and chemoresistance via endothelin-1/endothelin A receptor signaling |
| Q39264801 | Atomic level rendering of DNA-drug encounter. |
| Q57983113 | BAMLET kills chemotherapy-resistant mesothelioma cells, holding oleic acid in an activated cytotoxic state |
| Q34509157 | BODIPY-phosphane as a versatile tool for easy access to new metal-based theranostics. |
| Q88981142 | Bacterial Cytological Profiling Reveals the Mechanism of Action of Anticancer Metal Complexes |
| Q36379523 | Base-pair substitution hotspots in GAG and GCG nucleotide sequences in Escherichia coli K-12 induced by cis-diamminedichloroplatinum (II). |
| Q58864978 | Behind platinum's sparkle |
| Q39095158 | Bidentate ligands on osmium(VI) nitrido complexes control intracellular targeting and cell death pathways |
| Q41258864 | Bifunctional binding of cisplatin to DNA: why does cisplatin form 1,2-intrastrand cross-links with ag but not with GA? |
| Q34188228 | Binding of cis - and trans -Dichlorodiammineplatinum(II) to DNA: Evidence for Unwinding and Shortening of the Double Helix |
| Q33985189 | Binding of cis - and trans -dichlorodiammineplatinum(II) to the nucleosome core |
| Q33842478 | Binding of kinetically inert metal ions to RNA: the case of platinum(II). |
| Q60389814 | Bio-Metallodendrimers - Emerging Strategies in Metal-Based Drug Design |
| Q46504867 | Bioactive gold(i) complexes with 4-mercaptoproline derivatives |
| Q39773819 | Biochemical significance of the hard and soft acids and bases principle |
| Q70288533 | Biochemical studies on the potentiation of antitumor activity of cisplatin by adriamycin |
| Q54607960 | Biologic activity of a dinuclear Pd(II)-spermine complex toward human breast cancer. |
| Q39723723 | Biological activity of enantiomeric complexes [PtCl(2)L (2)] (L (2) is aromatic bisphosphanes and aromatic diamines). |
| Q41117364 | Biological activity of metal complexes. I. Interaction of Pt(II), Pd(II) and Rh(I) complexes with E. coli strains and with mice LS fibroblasts in vitro |
| Q39586908 | Biological activity of organometallic bismuth compounds |
| Q38872477 | Biologically active [Pd2L4](4+) quadruply-stranded helicates: stability and cytotoxicity. |
| Q43222524 | Biophysical studies on the stability of DNA intrastrand cross-links of transplatin. |
| Q60609930 | Bis(acetato)bis(1-methyl-4,5-diphenylimidazole)copper(II): Preparation, characterization, crystal structure, DNA strand breakage and cytogenetic effect |
| Q34184381 | Block copolymer micelles for drug delivery: design, characterization and biological significance |
| Q35615163 | Bmi1 essentially mediates podocalyxin-enhanced Cisplatin chemoresistance in oral tongue squamous cell carcinoma |
| Q39450806 | BnRCH gene inhibits cell growth of Hela cells through increasing the G2 phase of cell cycle |
| Q95841419 | Breathing New Life into the Mechanisms of Platinum Resistance in Lung Adenocarcinoma |
| Q38560599 | Bringing inorganic chemistry to life with inspiration from R. J. P. Williams |
| Q69636086 | CAP therapy for advanced, recurrent and/or metastatic malignant tumors of the head and neck |
| Q61817973 | Cancer Prevention and Therapy of Two Types of Gap Junctional Intercellular Communication⁻Deficient "Cancer Stem Cell" |
| Q24657512 | Cancer chemotherapy: past, present, and future--Part I |
| Q66971318 | Cancer of the ovary |
| Q46401371 | Cancer-Specific, Intracellular, Reductive Activation of Anticancer PtIV Prodrugs. |
| Q39047919 | Carbohydrate linked organotin(IV) complexes as human topoisomerase Iα inhibitor and their antiproliferative effects against the human carcinoma cell line |
| Q48250957 | Carboplatin ototoxicity: an animal model |
| Q70284489 | Carcinogenic effect of cisplatin (cis-diammine-dichloroplatinum (II), CDDP) in BD IX rats |
| Q71088174 | Carcinostatic effect of caffeine-8-ether-platinum-complexes |
| Q36611057 | Catalytic nanomedicine technology: copper complexes loaded on titania nanomaterials as cytotoxic agents of cancer cell |
| Q39206559 | Cationic arene ruthenium(II) complexes with chelating P-functionalized alkyl phenyl sulfide and sulfoxide ligands as potent anticancer agents. |
| Q54351595 | Cell response of Escherichia coli to cisplatin-induced stress. |
| Q58766014 | Cellular Pharmacology of Palladinum(III) Hematoporphyrin IX Complexes: Solution Stability, Antineoplastic and Apoptogenic Activity, DNA Binding, and Processing of DNA-Adducts |
| Q34089685 | Cellular Responses to Cisplatin‐Induced DNA Damage |
| Q68157850 | Changes in the cytoskeleton pattern of tumor cells by cisplatin in vitro |
| Q69414883 | Changes in the hydrodynamic properties of DNA induced by interaction with platinum (II) compounds |
| Q83202080 | Characteristic effect of an anticancer dinuclear platinum(II) complex on the higher-order structure of DNA |
| Q58135589 | Characterization and Purity Determination of Trans (±) 1,2-Diaminocyclohexane Platinum (Iv) Tetrachloride Using Liquid Chromatography With A Platinum Selective Detector |
| Q46103622 | Characterizing Pt-derived anticancer drugs from first principles: the case of oxaliplatin in aqueous solution |
| Q36085630 | Chemical approaches to the discovery and development of cancer therapies |
| Q36093381 | Chemistry and biology |
| Q28540744 | Chemopreventive evaluation of a Schiff base derived copper (II) complex against azoxymethane-induced colorectal cancer in rats |
| Q38779413 | Chemotherapeutic response to cisplatin-like drugs in human breast cancer cells probed by vibrational microspectroscopy. |
| Q51608334 | Chemotherapy of the squamous cell lung cancer LC-12 with 5-fluorouracil, cisplatin, carboplatin or iproplatin combinations. |
| Q68631789 | Chromatographic analysis of anticancer drugs |
| Q33788519 | Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer |
| Q34618357 | Circumventing tumor resistance to chemotherapy by nanotechnology |
| Q39718529 | Cis-diamminedichloroplatinum(II). A new antineoplastic agent derived from the group of heavy metal complexes (author's transl) |
| Q69796384 | Cis-dichlorodiammineplatinum (II): suppression of adjuvant-induced arthritis in rats |
| Q39798603 | Cisplatin (cis-diamminedichloroplatinum II) |
| Q38123245 | Cisplatin : an old drug with a newfound efficacy -- from mechanisms of action to cytotoxicity |
| Q48265802 | Cisplatin Binding to Biological Ligands Revealed at the Encounter Complex Level by IR Action Spectroscopy. |
| Q64063299 | Cisplatin Synergistically Enhances Antitumor Potency of Conditionally Replicating Adenovirus via p53 Dependent or Independent Pathways in Human Lung Carcinoma |
| Q30447637 | Cisplatin and aminoglycoside antibiotics: hearing loss and its prevention |
| Q92908024 | Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy |
| Q83427382 | Cisplatin as a cornerstone of modern chemotherapy |
| Q53756401 | Cisplatin increases sensitivity of human leukemic blasts to triazene compounds. |
| Q36893886 | Cisplatin induces differentiation of breast cancer cells |
| Q83984819 | Cisplatin prevents high mobility group box 1 release and is protective in a murine model of hepatic ischemia/reperfusion injury |
| Q36548702 | Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition |
| Q90149375 | Cisplatin-Based Chemotherapy of Human Cancers |
| Q33833882 | Cisplatin-based therapy: a neurological and neuropsychological review |
| Q38247492 | Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence |
| Q54284519 | Cisplatin-induced injury of the renal distal convoluted tubule is associated with hypomagnesaemia in mice. |
| Q37989844 | Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update |
| Q96135177 | Cisplatin-induced renal toxicity in elderly people |
| Q36039437 | Cisplatin-loaded porous Si microparticles capped by electroless deposition of platinum |
| Q37380106 | Cisplatin: a review of toxicities and therapeutic applications |
| Q34348474 | Cisplatin: from DNA damage to cancer chemotherapy. |
| Q39835716 | Cisplatin: synthesis, antitumour activity and mechanism of action |
| Q45361492 | Citrate inhibition of cisplatin reaction with DNA studied using fluorescently labeled oligonucleotides: implication for selectivity towards guanine |
| Q60212683 | Classical and Non-Classical Ruthenium-Based Anticancer Drugs: Towards Targeted Chemotherapy |
| Q41965116 | Clinical oncology and chemical thermodynamics |
| Q37551919 | Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin |
| Q39061133 | Co-delivery of oxaliplatin and demethylcantharidin via a polymer-drug conjugate |
| Q90139060 | Cobalt(II) Diphenylazodioxide Complexes Induce Apoptosis in SK-HEP-1 Cells |
| Q33798999 | Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions |
| Q46379865 | Combination therapeutic effect of cisplatin along with Solanum trilobatum on benzo(a)pyrene induced experimental lung carcinogenesis |
| Q33495298 | Comparative adverse effect profiles of platinum drugs. |
| Q39941240 | Comparative effects of alkylating agents and other anti-tumour agents on the intracellular level of adenosine 3′,5′-monophosphate in Walker carcinoma |
| Q40005317 | Comparison of the electronic properties, and thermodynamic and kinetic parameters of the aquation of selected platinum(II) derivatives with their anticancer IC50 indexes. |
| Q46604481 | Complexes of dibromo(ethylenediamine)-palladium(II) observed from aqueous solutions by electrospray mass spectrometry |
| Q50696009 | Complexes of dichloro(ethylenediamine)palladium(II) observed from aqueous solutions by electrospray mass spectrometry. |
| Q40648722 | Complexes of metals other than platinum as antitumour agents |
| Q39712535 | Comprehensive Vibrational Spectroscopic Investigation of trans,trans,trans-[Pt(N3)2(OH)2(py)2], a Pt(IV) Diazido Anticancer Prodrug Candidate |
| Q44712236 | Computational evidence for structural consequences of kiteplatin damage on DNA. |
| Q55844210 | Computational methods for the description of pharmacologically relevant platinum complexes – molecular structure and bond dissociation |
| Q33776520 | Confocal fluorescence microscopy studies of a fluorophore-labeled dirhodium compound: visualizing metal-metal bonded molecules in lung cancer (A549) cells |
| Q27666340 | Consequences of Cisplatin Binding on Nucleosome Structure and Dynamics |
| Q35128594 | Control and utilization of ruthenium and rhodium metal complex excited states for photoactivated cancer therapy |
| Q42576712 | Controlling Platinum, Ruthenium and Osmium Reactivity for Anticancer Drug Design. |
| Q39246803 | Coordination of Gly-Tyr · Pd(II) complex to ATP and ADP nucleotides |
| Q38667138 | Copper (II) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity status |
| Q37855898 | Copper, gold and silver compounds as potential new anti-tumor metallodrugs |
| Q35133330 | Copper-free click-chemistry platform to functionalize cisplatin prodrugs. |
| Q39898547 | Correlation between the toxicity of platinum drugs to L1210 leukaemia cells and their mutagenic properties |
| Q36044721 | Criteria for the selection of second-generation platinum compounds |
| Q59096780 | Cross-linking of Complementary Strands of DNA in Mammalian Cells by Antitumour Platinum Compounds |
| Q64033545 | Crystal structures of three thiourea (tu) complexes of Pt(II): trans-[(tu)2Pt(NH3)2]Cl2, trans-[(tu)2Pt(CH3NH2)2]Cl2·3H2O and [Pt(tu)4]Cl2 |
| Q64033546 | Crystal structures of two Pt(II) diamine compounds: trans-Pt(CH3NH2)2Cl2 and cis-Pt[(CH3)2NH]2Cl2 |
| Q58588998 | Current Developments in Pt(IV) Prodrugs Conjugated with Bioactive Ligands |
| Q92917085 | Current State of Platinum Complexes for the Treatment of Advanced and Drug-Resistant Breast Cancers |
| Q34612225 | Current status and future perspectives in the treatment of advanced testicular cancer |
| Q50122993 | Cyclometalated Pt(ii) complexes with a bidentate Schiff-base ligand displaying unexpected cis/trans isomerism: synthesis, structures and electronic properties. |
| Q51423158 | Cyclometallated iridium complexes inducing paraptotic cell death like natural products: synthesis, structure and mechanistic aspects. |
| Q40631806 | Cyclopalladated compounds as chemotherapeutic agents: Antitumor activity against a murine melanoma cell line |
| Q69414675 | Cyclophosphamide, tetrahydropyranyl-adriamycin, and cis-platinum in the treatment of head and neck adenocarcinoma |
| Q72597362 | Cytologic observations on the effects of metallocene dichlorides on human fibroblasts cultivated in vitro |
| Q40743027 | Cytotoxic effects of metal complexes of biogenic polyamines. I. Platinum(II) spermidine compounds: prediction of their antitumour activity. |
| Q73599284 | Cytotoxicity assessment of three therapeutic agents, cyclosporin-A, cisplatin and doxorubicin, with the ciliated protozoan Tetrahymena pyriformis |
| Q33696556 | Cytotoxicity of Pyrazine-Based Cyclometalated (C^Npz^C)Au(III) Carbene Complexes: Impact of the Nature of the Ancillary Ligand on the Biological Properties |
| Q35882449 | Cytotoxicity of a Ti(IV) compound is independent of serum proteins |
| Q35095042 | Cytotoxicity of cyclometalated platinum complexes based on tridentate NCN and CNN-coordinating ligands: remarkable coordination dependence |
| Q39548349 | Cytotoxicity of gold(I) N-heterocyclic carbene complexes assessed by using human tumor cell lines |
| Q39869132 | DFT-based QSAR and QSPR models of several cis-platinum complexes: solvent effect |
| Q45811861 | DNA binding and oxidative DNA cleavage activity of (mu-oxo)diiron(iii) complexes in visible light. |
| Q38293573 | DNA cleavage and binding selectivity of a heterodinuclear Pt-Cu(3-Clip-Phen) complex |
| Q50902552 | DNA interaction of europium(III) complex containing 2,2'-bipyridine and its antimicrobial activity. |
| Q34725611 | DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair. |
| Q35531287 | DNA repair mechanisms in cancer development and therapy |
| Q29615572 | DNA repair pathways as targets for cancer therapy |
| Q67322647 | DNA-platinum interactions in vitro with trans- and cis- Pt(NH3)2Cl2 |
| Q39992907 | David A. Karnofsky memorial lecture. Thoughts on chemical therapy |
| Q46165983 | Decomposition of Intermolecular Interactions in the Crystal Structure of Some Diacetyl Platinum(II) Complexes: Combined Hirshfeld, AIM, and NBO Analyses. |
| Q42946056 | Decursin Prevents Cisplatin-Induced Apoptosis via the Enhancement of Antioxidant Enzymes in Human Renal Epithelial Cells |
| Q40110955 | Degradable cisplatin-releasing core-shell nanogels from zwitterionic poly(beta -aminoester)-graft-PEG for cancer chemotherapy |
| Q39169444 | Degradation Kinetics of a Novel Antimitogenic and Antiviral Palladium(II) Coordination Compound |
| Q55165857 | Design, Synthesis, and Biological Evaluation of Benzimidazole-Derived Biocompatible Copper(II) and Zinc(II) Complexes as Anticancer Chemotherapeutics. |
| Q51307878 | Design, synthesis and biological evaluation of a novel series of glycosylated platinum(iv) complexes as antitumor agents. |
| Q52788217 | Design, synthesis, MTT assay, DNA interaction studies of platinum(II) complexes. |
| Q38974558 | Designing metallodrugs with nuclease and protease activity. |
| Q34088322 | Determination of hypersensitivity to genotoxic agents among Escherichia coli single gene knockout mutants |
| Q28484446 | Detoxifying antitumoral drugs via nanoconjugation: the case of gold nanoparticles and cisplatin |
| Q50576820 | Development of cis-platinum-induced hearing loss in guinea pigs. |
| Q47672975 | Differences in cisplatin distribution in sensitive and resistant ovarian cancer cells: a TEM/NanoSIMS study. |
| Q92154985 | Different Effects of Cisplatin and Transplatin on the Higher-Order Structure of DNA and Gene Expression |
| Q42854210 | Differential effect of cis-platinum (cis-diamminedichloroplatinum) on regulation of liver and kidney haem and haemoprotein metabolism. Possible involvement of gamma-glutamyl-cycle enzymes |
| Q47142435 | Dihydroartemisinin inhibits EMT induced by platinum-based drugs via Akt-Snail pathway |
| Q48058684 | Direct measurement of interaction forces between a platinum dichloride complex and DNA molecules. |
| Q66955456 | Dissociation of double-stranded poly(I) · poly(C) by cis-diammine-dichloro-Pt(II) |
| Q39540757 | Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells. |
| Q36229392 | Drug Repurposing for Cancer Therapy. |
| Q37845248 | Drug therapy of cancer |
| Q90351538 | Dual Photoreactivity of a New Rh2(II,II) Complex for Biological Applications |
| Q30993331 | Effect of Different Z-Inducers on the Stabilization of Z Portion in BZ-DNA Sequence: Correlation Between Experimental and Simulation Data. |
| Q38014817 | Effect of cis-platinum on heme, drug, and steroid metabolism pathways: possible involvement in nephrotoxicity and infertility |
| Q40026912 | Effect of cis-platinum(II)diamminodichloride on cell division of Hyphomicrobium and Caulobacter |
| Q36767060 | Effect of cis-platinum(II)diamminodichloride on wild type and deoxyribonucleic acid repair deficient mutants of Escherichia coli |
| Q67552719 | Effect of coadministration of selenite on the toxicity and antitumor activity of cis-diamminedichloroplatinum (II) given repeatedly to mice |
| Q47715751 | Effect of rhodium (III) complex on experimental carcinogenesis in the livers of rats treated with thioacetamide |
| Q51674397 | Effect of whole body hyperthermia on cis-diamminedichloroplatinum (II)-induced antitumour activity and tissue Pt-distribution: do anaesthetics influence the therapeutic ratio? |
| Q42373306 | Effective prevention of the nephrotoxicity of cis-platin (CDDP) by administration of sodium 2-mercaptoethane-sulfonate (MESNA) in rats |
| Q37628495 | Effects of 1,25(OH)₂D₃ on Cancer Cells and Potential Applications in Combination with Established and Putative Anti-Cancer Agents. |
| Q52480589 | Effects of carboplatin on the testis. A histological study. |
| Q59649953 | Effects of cobalt (III) complexes on growth and metabolism of Escherichia coli |
| Q43334087 | Effects of granisetron and its combination with dexamethasone on cisplatin-induced delayed emesis in the ferret |
| Q72065588 | Effects of intralesional injection of cisplatin dissolved in urografin and lipiodol on Ehrlich ascites tumor and normal tissues of CD-1 mice |
| Q34393918 | Effects of monofunctional platinum agents on bacterial growth: a retrospective study |
| Q85570391 | Effects of platinic chloride on Tetrahymena pyriformis GL |
| Q52277315 | Effects on the development of offspring of female mice exposed to platinum sulfate or sodium hexachloroplatinate during pregnancy or lactation. |
| Q60909024 | Efficacy and tolerability of BP-C1 in metastatic breast cancer: a Phase II, randomized, double-blind, and placebo-controlled Thai multi-center study |
| Q43969526 | Electrolytic ablation as an adjunct to liver resection: experimental studies of predictability and safety |
| Q24804655 | Electrolytic ablation of the rat pancreas: a feasibility trial |
| Q51205603 | Electron scattering from gas phase cis-diamminedichloroplatinum(II): quantum analysis of resonance dynamics. |
| Q36069093 | Electron transfer-based combination therapy of cisplatin with tetramethyl-p-phenylenediamine for ovarian, cervical, and lung cancers. |
| Q33612466 | Electrospun Poly(ε-caprolactone) Composite Nanofibers with Controlled Release of Cis-Diamminediiodoplatinum for a Higher Anticancer Activity |
| Q64268057 | Elucidation of the Mechanism of Action for Metal Based Anticancer Drugs by Mass Spectrometry-Based Quantitative Proteomics |
| Q55172138 | Emerging role of long non-coding RNAs in cisplatin resistance. |
| Q35000093 | Encapsulation of Pt(IV) Prodrugs within a Pt(II) Cage for Drug Delivery |
| Q35242640 | Endothelin-1 promotes osteosarcoma cell invasion and survival against cisplatin-induced apoptosis |
| Q71236723 | Energy-dispersive X-ray fluorescence determination of platinum in plasma, urine, and cerebrospinal fluid of patients administered cis-dichlorodiammineplatinum(II) |
| Q41488663 | Enhanced inhibition of both cellular protein synthesis and malate dehydrogenase by aged aquoplatinum(II) complexes |
| Q39081353 | Enhancement of cisplatin cytotoxicity in combination with herniarin in vitro |
| Q34704011 | Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer |
| Q37085878 | Enhancing the efficacy of cisplatin in ovarian cancer treatment - could arsenic have a role. |
| Q36377590 | Enzyme-Instructed Intracellular Molecular Self-Assembly to Boost Activity of Cisplatin against Drug-Resistant Ovarian Cancer Cells |
| Q64238257 | Evaluation of Polymer Nanoformulations in Hepatoma Therapy by Established Rodent Models |
| Q39663017 | Evaluation of a Schiff base copper complex compound as potent anticancer molecule with multiple targets of action |
| Q37344013 | Evolution of energy metabolism, stem cells and cancer stem cells: how the warburg and barker hypotheses might be linked. |
| Q90292067 | Exonuclease 1 (Exo1) Participates in Mammalian Non-Homologous End Joining and Contributes to Drug Resistance in Ovarian Cancer |
| Q44011744 | Expeditious syntheses of two carbohydrate-linked cisplatin analogs |
| Q57816479 | Exploration of biological activities of alkyne arms containing Cu(ii) and Ni(ii) complexes: syntheses, crystal structures and DFT calculations |
| Q52349456 | Exploration of selected electronic characteristics of half-sandwich organoruthenium(II) β-diketonate complexes. |
| Q70714242 | Ferricenium complexes: a new type of water-soluble antitumor agent |
| Q24236119 | Fluid and diuretic therapy for preventing cisplatin-induced nephrotoxicity |
| Q24242032 | Fluid and diuretic therapy for preventing cisplatin-induced nephrotoxicity |
| Q38863948 | Fluorescent mixed ligand copper(II) complexes of anthracene-appended Schiff bases: studies on DNA binding, nuclease activity and cytotoxicity |
| Q56978022 | Folding Kinetics of Single Human Telomeric G-Quadruplex Affected by Cisplatin |
| Q64390093 | Formation and stability of interstrand cross-links induced by cis- and trans-diamminedichloroplatinum (II) in the DNA of Saccharomyces cerevisiae strains differing in repair capacity |
| Q53029341 | Fosfomycin Does not Reduce Cytostatic Activity of Cis-Platinum Against Human Osteosarcoma Cell Lines in Vitro |
| Q35593353 | From cisplatin to artificial nucleases--the role of metal ion-nucleic acid interactions in biology |
| Q52739129 | Functional metal complexes from CuAAC "click" bidentate and tridentate pyridyl-1,2,3-triazole ligands. |
| Q39761093 | Gadolinium texaphyrin (Gd-Tex)-malonato-platinum conjugates: synthesis and comparison with carboplatin in normal and Pt-resistant cell lines |
| Q42131038 | Gap Junction Enhancer Potentiates Cytotoxicity of Cisplatin in Breast Cancer Cells |
| Q39428059 | Genetic variation in the DNA repair pathway as a potential determinant of response to platinum-based chemotherapy in breast cancer. |
| Q40807070 | Genomic imbalances associated with acquired resistance to platinum analogues |
| Q26851196 | Genotoxic anti-cancer agents and their relationship to DNA damage, mitosis, and checkpoint adaptation in proliferating cancer cells |
| Q28378257 | Gold(I) complexes as antimicrobial agents |
| Q58921526 | Gold(iii) complexes inhibit growth of cisplatin-resistant ovarian cancer in association with upregulation of proapoptotic PMS2 gene |
| Q47447102 | Green synthesis palladium nanoparticles mediated by white tea (Camellia sinensis) extract with antioxidant, antibacterial, and antiproliferative activities toward the human leukemia (MOLT-4) cell line |
| Q38043422 | Group-10 metal complexes of biological molecules and related ligands: structural and functional properties |
| Q77636528 | Growth and differentiation of bone marrow hematopoietic cells in mice bearing Ehrlich ascite tumor and treated with Dicyclopentadienildichlorotitanium (IV) |
| Q90376633 | HOXB7 mediates cisplatin resistance in esophageal squamous cell carcinoma through involvement of DNA damage repair |
| Q46521670 | HPMA copolymer platinates as novel antitumour agents: in vitro properties, pharmacokinetics and antitumour activity in vivo |
| Q36082052 | Half-sandwich RuCl2(η(6)-p-cymene) core complexes containing sulfur donor aroylthiourea ligands: DNA and protein binding, DNA cleavage and cytotoxic studies |
| Q54056992 | HeLa cell transformants overproducing mouse metallothionein show in vivo resistance to cis-platinum in nude mice. |
| Q42130456 | Heteroleptic Copper(I) Complexes of "Scorpionate" Bis-pyrazolyl Carboxylate Ligand with Auxiliary Phosphine as Potential Anticancer Agents: An Insight into Cytotoxic Mode. |
| Q62082145 | Highly Water-Soluble Cyclopentadienyl and Indenyl Molybdenum(II) Complexes - Second Generation of Molybdenum-Based Cytotoxic Agents |
| Q35756295 | Highly and Broad-Spectrum In Vitro Antitumor Active cis-Dichloridoplatinum(II) Complexes with 7-Azaindoles |
| Q34297886 | Highly potent metallopeptide analogues of luteinizing hormone-releasing hormone. |
| Q39864467 | Highly selective apoptotic cell death induced by halo-salane titanium complexes |
| Q28484603 | Histological changes in kidney and liver of rats due to gold (III) compound [Au(en)Cl(2)]Cl |
| Q44631406 | How Strong Can the Bend Be on a DNA Helix from Cisplatin? DFT and MP2 Quantum Chemical Calculations of Cisplatin-Bridged DNA Purine Bases |
| Q39185517 | Human cancerous and healthy cell cytotoxicity studies of a chiral μ-dicarbene-digold(I) metallamacrocycle |
| Q62140985 | Hydration of cis- and trans-platin: A pseudopotential treatment in the frame of a G3-type theory for platinum complexes |
| Q34531571 | Hydrogel Nanoparticles with Thermally Controlled Drug Release |
| Q38000483 | Hyphenated techniques as tools for speciation analysis of metal-based pharmaceuticals: developments and applications |
| Q61799902 | Hypoxia-targeted drug delivery |
| Q34052005 | Identification of chemoresistant factors by protein expression analysis with iTRAQ for head and neck carcinoma |
| Q67797213 | Immediate (type I) allergic responses to platinum compounds |
| Q40461128 | Immunological and spectroscopic studies of poly(dG-dC).poly(dG-dC) modified by cis-diamminedichloroplatinum(II). |
| Q41430824 | Immunosuppression by Platinum Diamines |
| Q40886027 | Immunosuppression with cis -Platinum (II) Diammino-dichloride: Effect on Antibody Plaque-Forming Spleen Cells |
| Q56763984 | Impact of drug formulation and free platinum/cisplatin ratio on hypersensitivity reactions to cisplatin: formulation matters |
| Q88917536 | Impact of various lipophilic substituents on ruthenium(II), rhodium(III) and iridium(III) salicylaldimine-based complexes: synthesis, in vitro cytotoxicity studies and DNA interactions |
| Q43029692 | Improvements in the Synthesis and Understanding of the Iodo-bridged Intermediate en Route to the Pt(IV) Prodrug Satraplatin |
| Q58079350 | In Vitro Anti-Atherogenic Properties of N-Heterocyclic Carbene Aurate(I) Compounds |
| Q36001231 | In Vitro and In Vivo Studies of Non-Platinum-Based Halogenated Compounds as Potent Antitumor Agents for Natural Targeted Chemotherapy of Cancers |
| Q42292369 | In situ generated D-peptidic nanofibrils as multifaceted apoptotic inducers to target cancer cells |
| Q70813836 | In the search for new anticancer drugs. VII. Platinum complexes of diaziridines and azetidine |
| Q35216231 | In vitro and in vivo antitumor activities and DNA binding mode of five coordinated cyclometalated organoplatinum(II) complexes containing biphosphine ligands |
| Q58838263 | In vitro and in vivo studies into the biological activities of 1,10-phenanthroline, 1,10-phenanthroline-5,6-dione and its copper(ii) and silver(i) complexes |
| Q39952629 | In vitro anticancer activity and biologically relevant metabolization of organometallic ruthenium complexes with carbohydrate-based ligands |
| Q39027164 | In vitro cytotoxic activities, DNA-, and BSA-binding studies of a new dinuclear copper(II) complex with N-[3-(dimethylamino)propyl]-N'-(2-carboxylatophenyl)-oxamide as ligand |
| Q41503822 | In vitro plasma binding of some second generation antitumor platinum complexes |
| Q53116557 | In vitro studies on cisplatin focusing on kinetic aspects of intracellular chemistry by LC-ICP-MS. |
| Q53028113 | In vitro studies on genotoxicity and cytotoxicity of the anticancer drugs cisplatin and cofplaton, a caffeine-8-ether plus cisplatinum compound |
| Q39782222 | In vivo comparative study of the cytotoxicity of a liposomal formulation of cisplatin (lipoplatin™). |
| Q67716194 | Increased mitochondrial uptake of rhodamine 123 by CDDP treatment |
| Q38806350 | Induction of intrinsic and extrinsic apoptosis through oxidative stress in drug-resistant cancer by a newly synthesized Schiff base copper chelate |
| Q46912600 | Inelastic neutron scattering study of Pt(II) complexes displaying anticancer properties |
| Q62274210 | Influence of DFT Functionals and Solvation Models on the Prediction of Far-Infrared Spectra of Pt-Based Anticancer Drugs: Why Do Different Complexes Require Different Levels of Theory? |
| Q62851949 | Influence of antineoplastic drugs on morphine analgesia and on morphine tolerance |
| Q68671238 | Influence of frusemide on cis-dichlorodiammineplatinum (II) pharmaco-kinetics |
| Q60212615 | Influence of the Diketonato Ligand on the Cytotoxicities of [Ru(η6-p-cymene)(R2acac)(PTA)]+ Complexes (PTA = 1,3,5-triaza-7-phosphaadamantane) |
| Q45060673 | Influence of time and chloride ions on the interaction of cisplatin with human albumin in-vitro |
| Q45811404 | Inhibition of Cold VarIant of Influenza Virus by Selected Chemicals |
| Q34249679 | Inhibition of avian myeloblastosis virus reverse transcriptase and virus inactivation by metal complexes of isonicotinic acid hydrazide |
| Q38981537 | Inhibition of cancer derived cell lines proliferation by synthesized hydroxylated stilbenes and new ferrocenyl-stilbene analogs. Comparison with resveratrol. |
| Q70439651 | Inhibition of cell division by sodium chloroiridate |
| Q55060877 | Inhibition of cisplatin-mediated DNA damage in vitro by ribonucleotides. |
| Q70456367 | Inhibition of leucine aminopeptidase and malate dehydrogenase by aquoplatinum (II) complexes |
| Q70586156 | Inhibition of lymphocyte blastogenesis by platinum compounds |
| Q37364815 | Inhibition of transcription by platinum antitumor compounds |
| Q72605126 | Inhibitory studies of DNA, RNA and protein synthesis in Escherichia coli by platinum containing complexes |
| Q42118007 | Innovative Use of Palladium Compounds to Selectively Detect Live Enterobacteriaceae Cells in Milk by Polymerase Chain Reaction |
| Q91971712 | Inositol-triphosphate 3-kinase B confers cisplatin resistance by regulating NOX4-dependent redox balance |
| Q36959078 | Insights into RNA binding by the anticancer drug cisplatin from the crystal structure of cisplatin-modified ribosome |
| Q64945054 | Insulin Release Mechanism Modulated by Toxins Isolated from Animal Venoms: From Basic Research to Drug Development Prospects. |
| Q42592163 | Interaction of 5'-Guanosine Monophosphate with Organotin(IV) Moieties: Synthesis, Structural Characterization, and Anti-Inflammatory Activity |
| Q40048032 | Interaction of Pt(II) complexes with DNAs from various sources. A circular dichroism study |
| Q44637765 | Interaction of anticancer drug cisplatin with guanine: Density functional theory and surface‐enhanced Raman spectroscopy study |
| Q41141577 | Interaction of cis-diamminedichloroplatinum(II) with phi X174 DNA. |
| Q52996234 | Interaction of cis-dichlorodiammineplatinum (II) with DNA |
| Q39584594 | Interaction of rac-[M(diimine)3]2+ (M=Co, Ni) complexes with CT DNA: role of 5,6-dmp ligand on DNA binding and cleavage and cytotoxicity |
| Q67018850 | Interaction of rhodium(III) with DNA |
| Q73295356 | Interaction of sodium chloroplatinate and iproplatin with metallothionein in vivo |
| Q67324954 | Interactions of Cis- and Trans-platinum(II) complexes with dehydrogenase enzymes in the presence of different mono- and polynucleotides: Evidence for a ternary complex |
| Q47906101 | Interactions of an antitumor platinum compound with deoxyribonucleic acid, histones, l-amino acids, poly-l-amino acids, nucleosides and nucleotides |
| Q27687736 | Interactions of gold-based drugs with proteins: crystal structure of the adduct formed between ribonuclease A and a cytotoxic gold(III) compound |
| Q54252471 | Interactions of platinum complexes, peptides, methionine and dehydrogenases. |
| Q34663069 | Interactions of platinum metals and their complexes in biological systems |
| Q50210771 | Interactions of the "piano-stool" [ruthenium(II)(η(6) -arene)(quinolone)Cl](+) complexes with water; DFT computational study. |
| Q39140230 | Intracellular water - an overlooked drug target? Cisplatin impact in cancer cells probed by neutrons. |
| Q41722709 | Introduction and overview of noninvasive drug monitoring |
| Q39407436 | Investigational drugs under study by the United States National Cancer Institute |
| Q67428098 | Investigations into the mechanisn of action of antitumour platinum compounds: Time- and dose-dependent changes in the alkaline sucrose gradient sedimentation profiles of DNA from hamster cells treated with cis-platinum(II) diamminedichloride |
| Q39371239 | Involvement of cytochrome P450 in cisplatin treatment: implications for toxicity |
| Q43856063 | Ionic rhenocene derivatives with antitumor activity |
| Q69609843 | Ionic titanocene complexes: a new type of antitumor agent |
| Q38710506 | Is matching ruthenium with dithiocarbamato ligands a potent chemotherapeutic weapon in oncology? |
| Q40586878 | Isomer abundance of bis(beta-diketonato) complexes of titanium(IV). Crystal structures of the antitumor compound budotitane [Ti(IV)(bzac)(2)(OEt)(2)] and of its dichloro-derivative [Ti(IV)(bzac)(2)Cl(2)] (bzac=1-phenylbutane-1,3-dionate). |
| Q36291991 | JWA reverses cisplatin resistance via the CK2-XRCC1 pathway in human gastric cancer cells |
| Q30972381 | Kinetic study of azole-bridged dinuclear platinum(II) complexes reacting with a hairpin-stabilized double-stranded oligonucleotide |
| Q52076226 | Kinetics and mechanism for reduction of anticancer-active tetrachloroam(m)ine platinum(IV) compounds by glutathione. |
| Q38298266 | Kinetics of cisplatin binding to short r(GG) containing miRNA mimics - influence of Na(+)versus K(+), temperature and hydrophobicity on reactivity |
| Q68239828 | Leukemia and the reducing property of viruses |
| Q58063439 | Ligation of anti-cancer drugs to self-assembling ultrashort peptides by click chemistry for localized therapy |
| Q57345360 | Light Harvesting and Photoemission by Nanoparticles for Photodynamic Therapy |
| Q50909229 | Lipid Flip-Flop and Pore Nucleation on Zwitterionic Bilayers are Asymmetric under Ionic Imbalance. |
| Q52535446 | Lipophilic gold(I) complexes with 1,3,4-oxadiazol-2-thione or 1,3-thiazolidine-2-thione moieties: synthesis and their cytotoxic and antimicrobial activities. |
| Q89622527 | Long Non-coding RNAs Involved in Resistance to Chemotherapy in Ovarian Cancer |
| Q41504946 | Long term effect of Cis-Diamminedichloride platinum (CDDP) on renal function and structure in man |
| Q38814705 | Luminescent bioactive NHC-metal complexes to bring light into cells |
| Q39528351 | M2L4 coordination capsules with tunable anticancer activity upon guest encapsulation. |
| Q39687663 | MDR1 mediated chemoresistance: BMI1 and TIP60 in action |
| Q41194560 | Matrix Density Engineering of Hydrogel Nanoparticles with Simulation-Guided Synthesis for Tuning Drug Release and Cellular Uptake |
| Q36904002 | Mechanism elucidation of the cis-trans isomerization of an azole ruthenium-nitrosyl complex and its osmium counterpart |
| Q26996320 | Mechanisms of Cisplatin nephrotoxicity |
| Q64390568 | Mechanisms of cisplatin (cis-diamminodichloroplatinum II)-induced cytotoxicity and genotoxicity in yeast |
| Q37392185 | Mechanistic Studies of the Anticancer Activity of An Octahedral Hexanuclear Pt(II) Cage. |
| Q38034439 | Mechanistic studies on the reactions of platinum(II) complexes with nitrogen- and sulfur-donor biomolecules |
| Q34514293 | Medicinal agents incorporating the 1,2-diamine functionality |
| Q39270889 | Melanoma tumor inhibition by tetrachlorido(O,O'-dibutyl-ethylenediamine-N,N'-di-3-propionate)platinum(IV) complex: in vitro and in vivo investigations. |
| Q45174087 | Mercaptoalkylamine Coordination Compounds of Platinum(II) and Palladium(II) and Their Anticancer Activity |
| Q69015737 | Metabolism of platinum [14cethylenediamine dichloride in the rat |
| Q48185242 | Metal Ions Effectively Ablate the Action of Botulinum Neurotoxin A. |
| Q35836648 | Metal and metalloid containing natural products and a brief overview of their applications in biology, biotechnology and biomedicine. |
| Q38271731 | Metal complex interactions with DNA. |
| Q91913177 | Metal complexes driven from Schiff bases and semicarbazones for biomedical and allied applications: a review |
| Q68286163 | Metallothionein induction prevents toxic side effects of cisplatin and adriamycin used in combination |
| Q91685000 | Methionine Binding to Dirhodium(II) Tetraacetate |
| Q36467141 | Metoclopramide enhances the effect of cisplatin on xenografted squamous cell carcinoma of the head and neck |
| Q42241395 | Microbial growth inhibition by alternating electric fields |
| Q37467770 | Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice. |
| Q33564338 | Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate |
| Q39052398 | Mitochondria are the primary target in the induction of apoptosis by chiral ruthenium(II) polypyridyl complexes in cancer cells |
| Q39638924 | Mitochondrial mode of action of a thymidine-based cisplatin analogue breaks resistance in cancer cells |
| Q39993736 | Mixed ligand ruthenium(II) complexes of bis(pyrid-2-yl)-/bis(benzimidazol-2-yl)-dithioether and diimines: study of non-covalent DNA binding and cytotoxicity. |
| Q38969205 | Mixed-ligand ruthenium polypyridyl complexes as apoptosis inducers in cancer cells, the cellular translocation and the important role of ROS-mediated signaling |
| Q37843695 | Mode of action and biosynthesis of the azabicycle-containing natural products azinomycin and ficellomycin. |
| Q73481429 | Modified rice bran beneficial for weight loss of mice as a major and acute adverse effect of Cisplatin |
| Q73335667 | Modifying the properties of platinum (IV) complexes in order to increase biological effectiveness |
| Q35758048 | Molecular mechanisms of resistance and toxicity associated with platinating agents |
| Q31630775 | Molecular structure and cytotoxicity of 3D-transition metal complexes capable to form a stable metal-nitrogen bond |
| Q38823861 | Mono- and di-bromo platinum(IV) prodrugs via oxidative bromination: synthesis, characterization, and cytotoxicity. |
| Q37282213 | Monofunctional and higher-valent platinum anticancer agents. |
| Q50063144 | Monomeric and dimeric coordinatively saturated and substitutionally inert Ru(ii) polypyridyl complexes as anticancer drug candidates. |
| Q57752749 | Mononuclear copper(ii) complexes with 3,5-substituted-4-salicylidene-amino-3,5-dimethyl-1,2,4-triazole: synthesis, structure and potent inhibition of protein tyrosine phosphatases |
| Q38829453 | Mononuclear iron(iii) complexes of tridentate ligands with efficient nuclease activity and studies of their cytotoxicity |
| Q38310005 | More pronounced salt dependence and higher reactivity for platination of the hairpin r(CGCGUUGUUCGCG) compared with d(CGCGTTGTTCGCG). |
| Q64033408 | Multiplicity of metal ion binding patterns to nucleobases |
| Q30883067 | Multivalent Antibiotics via Metal Complexes: Potent Divalent Vancomycins against Vancomycin-Resistant Enterococci |
| Q66894876 | Mutagenic properties of CIS-Platinum(II)diammino-dichloride in Escherichia coli |
| Q38980214 | N-Polybenzylated alicyclic 1,2-diamines: cytotoxicity and G1 phase arrest in cancer cell line |
| Q39138998 | N6-benzyladenosine derivatives as novel N-donor ligands of platinum(II) dichlorido complexes. |
| Q34338695 | Nanocarriers for delivery of platinum anticancer drugs. |
| Q37042860 | Nanoparticle encapsulation of mitaplatin and the effect thereof on in vivo properties |
| Q38723829 | Nanoparticle formulations of cisplatin for cancer therapy |
| Q52744411 | Nanoparticles of metal-organic cages designed to encapsulate platinum-based anticancer agents. |
| Q42361372 | Nanotoxicology and Metalloestrogens: Possible Involvement in Breast Cancer |
| Q34690068 | Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity |
| Q42368069 | Neuro-protective effect of rutin against Cisplatin-induced neurotoxic rat model |
| Q46487990 | New Insights into the Reactivity of Cisplatin with Free and Restrained Nucleophiles: Microsolvation Effects and Base Selectivity in Cisplatin-DNA Interactions. |
| Q40491603 | New cisplatin analogues in development. A review |
| Q34914365 | New clues for platinum antitumor chemistry: kinetically controlled metal binding to DNA. |
| Q33859961 | New oral chemotherapeutic agents for lung cancer |
| Q40149023 | New platinum complexes in clinical trials |
| Q34215909 | New platinum complexes with anti-tumour activity |
| Q39717597 | Noble Metal Complexes in Cancer Chemotherapy |
| Q36985163 | Non-DNA-binding platinum anticancer agents: Cytotoxic activities of platinum-phosphato complexes towards human ovarian cancer cells |
| Q42155449 | Non-traditional platinum compounds for improved accumulation, oral bioavailability, and tumor targeting |
| Q33852968 | Noninvasive measurements for studying the tumoral pharmacokinetics of platinum anticancer drugs in solid tumors |
| Q39031995 | Novel heterobimetallic radiotheranostic: preparation, activity, and biodistribution |
| Q48015270 | Novel nanocrystals as a platinum-delivery vehicle for chemotherapy |
| Q53636499 | Novel oxaliplatin derivatives with 1-(substituted benzyl)azetidine-3,3-dicarboxylate anions. Synthesis, cytotoxicity, and interaction with DNA. |
| Q39459292 | Novel platinum(II) and palladium(II) complexes of thiosemicarbazones derived from 5-substitutedthiophene-2-carboxaldehydes and their antiviral and cytotoxic activities |
| Q37461061 | Novel strategies for reversing platinum resistance |
| Q45162711 | Novel thiocyanato complexes with potent cytotoxic and antimicrobial properties |
| Q68045195 | Novel, quinone-thiosemicarbazone hybrid (QTSCHY) non-platinum antitumor agents: inhibition of DNA biosynthesis in P388 lymphocytic cells by coordinatively unsaturated copper(II) and iron(III) complexes of naphthoquinone thiosemicarbazones |
| Q40121686 | Occupational asthma: Review of present clinical and immunologic status |
| Q38767028 | Oligonucleotide structure: a decade of results from single crystal X-ray diffraction studies |
| Q39399932 | On the binding modes of metal NHC complexes with DNA secondary structures: implications for therapy and imaging |
| Q35665803 | Oncology: its scope and prospects |
| Q28829576 | One-dimensional Magnus-type platinum double salts |
| Q39229950 | Organometallic anticancer agents that interfere with cellular energy processes: a subtle approach to inducing cancer cell death |
| Q42555974 | Organometallic cis-Dichlorido Ruthenium(II) Ammine Complexes |
| Q38848959 | Overcoming tumor resistance to cisplatin through micelle-mediated combination chemotherapy |
| Q90371047 | Oxaliplatin Pt(IV) prodrugs conjugated to gadolinium-texaphyrin as potential antitumor agents |
| Q37242664 | Oxaliplatin-based chemotherapy in the management of colorectal cancer |
| Q33761590 | Oxidative DNA double strand breaks and autophagy in the antitumor effect of sterically hindered platinum(II) complexes in NSCLCs |
| Q43051494 | Oxidative halogenation of cisplatin and carboplatin: synthesis, spectroscopy, and crystal and molecular structures of Pt(IV) prodrugs |
| Q33594393 | Oxoaporphine Metal Complexes (CoII, NiII, ZnII) with High Antitumor Activity by Inducing Mitochondria-Mediated Apoptosis and S-phase Arrest in HepG2. |
| Q69571206 | Pattern of toxicity by titanocene dichloride in mice. Blood and urine chemical parameters |
| Q41915835 | Pentamethylcyclopentadienyl-rhodium and iridium complexes containing (N^N and N^O) bound chloroquine analogue ligands: synthesis, characterization and antimalarial properties |
| Q38870736 | Peptide Bioconjugates of Electron-Poor Metallocenes: Synthesis, Characterization, and Anti-Proliferative Activity |
| Q38166233 | Personalizing colon cancer therapeutics: targeting old and new mechanisms of action. |
| Q37946235 | Perspective: the potential of pyrazole-based compounds in medicine |
| Q38330216 | Pharmacogenetics of chemotherapy-induced nausea and vomiting |
| Q47309064 | Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1. |
| Q61828298 | Pharmacokinetics and Tissue Distribution of Cisplatin and Conjugates of Cisplatin with Carboxymethyldextran and A5B7 Monoclonal Antibody in CD1 Mice |
| Q38275908 | Pharmacokinetics and tissue distribution of novel platinum containing anticancer agent BP-C1 studied in rabbits using sector field inductively coupled plasma mass spectrometry |
| Q33426796 | Pharmacokinetics of (glycolate-0,0')-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin |
| Q35112827 | Pharmacological and molecular effects of platinum(II) complexes involving 7-azaindole derivatives. |
| Q33670435 | Pharmacological applications of inorganic complexes |
| Q69358010 | Phase I clinical trial of combined therapy with 5-FU (NSC 19893) and cis-platinum (II) diaminedichloride (NSC 119875) |
| Q51199413 | Photochemistry and DNA photocleavage by a new unsupported dirhodium(II,II) complex. |
| Q35147166 | Photoinduced interactions of two dirhodium complexes with d(GTCGAC)2 probed by 2D NOESY. |
| Q30806098 | Photoinduced intercalation and coordination of a dirhodium complex to DNA: dual DNA binding |
| Q77811663 | Physicochemical factors for cytotoxic activity in platinum dinuclear complexes with pyrimidine and imide ligands |
| Q56659409 | Platin-Komplexe in der Krebstherapie |
| Q58486684 | Platinum Complexes as Anti-Cancer Drugs: Modeling of Structure, Activation and Function |
| Q58993871 | Platinum and Palladium Polyamine Complexes as Anticancer Agents: The Structural Factor |
| Q36322728 | Platinum antitumour agents: a review of (bio)analysis |
| Q43620915 | Platinum carboxylato-pendant-arm macrocycles: structure, redox properties and anti-cancer potential |
| Q38791247 | Platinum complexes as light promoted anticancer agents: a redefined strategy for controlled activation |
| Q67234080 | Platinum complexes inhibit ATP‐driven basic dye uptake in lysosomes from rat liver |
| Q53728172 | Platinum coordination complexes in cancer chemotherapy. |
| Q39428343 | Platinum nanoparticles in nanobiomedicine. |
| Q44485929 | Platinum(II) catalysis and radical intervention in reductions of platinum(IV) antitumor drugs by ascorbic acid |
| Q92268928 | Platinum(IV)-Ferrocene Conjugates and Their Cyclodextrin Host-Guest Complexes |
| Q41007441 | Platinum-conjugated antibodies for application in mass cytometry |
| Q90049509 | Poly(3-hydroxi-butyrate-co-3-hydroxy-valerate) (PHB-HV) microparticles loaded with holmium acetylacetonate as potential contrast agents for magnetic resonance images |
| Q55286461 | Polyethylene glycol-conjugated HER2-targeted peptides as a nuclear imaging probe for HER2-overexpressed gastric cancer detection in vivo. |
| Q36253687 | Polymeric Micelle-Mediated Delivery of DNA-Targeting Organometallic Complexes for Resistant Ovarian Cancer Treatment |
| Q37211504 | Polymeric micelles from poly(ethylene glycol)-poly(amino acid) block copolymer for drug and gene delivery |
| Q33506479 | Polyvalent oligonucleotide gold nanoparticle conjugates as delivery vehicles for platinum(IV) warheads |
| Q50649669 | Possible involvement of the lipoxygenase and leukotriene signaling pathways in cisplatin-mediated renal toxicity. |
| Q39888799 | Post-translational and transcriptional regulation of glycolipid glycosyltransferase genes in apoptotic breast carcinoma cells: VII. Studied by DNA-microarray after treatment with L-PPMP. |
| Q42281419 | Potent antitumour activity of (-)-(R)-2-aminomethylpyrrolidine (1,1-cyclobutanedicarboxylato)platinum(II) monohydrate (DWA2114R) against advanced L1210 leukaemia in mice |
| Q39452671 | Potent inhibition of protein tyrosine phosphatases by quinquedentate binuclear copper complexes: synthesis, characterization and biological activities. |
| Q40864105 | Potential Carcinostatic Activity of Metal Complexes |
| Q39175635 | Potentially cytotoxic new copper(II) hydrazone complexes: synthesis, crystal structure and biological properties |
| Q92637158 | Preclinical Evaluation of 1,2-Diamino-4,5-Dibromobenzene in Genetically Engineered Mouse Models of Pancreatic Cancer |
| Q41704067 | Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay |
| Q64889081 | Preferential Interstrand Cross-Linking of DNA Rich in Guanine and Cytosine by cis-Dichlorodiammineplatinum(II) |
| Q33465444 | Preliminary clinical experience withcis-diamminedichloroplatinum (II) (NSC 119875, CACP) |
| Q71463869 | Preliminary studies on the inhibitory effect of novel Pd(II) complexes of vitamin B6 on cell divisions |
| Q37395694 | Preparation of mammalian expression vectors incorporating site-specifically platinated-DNA lesions. |
| Q98293128 | Probing DNA-Cleavage Efficiencies of Copper(II) Complexes: A Computational Perspective |
| Q45145537 | Probing the biological evaluations of a new designed Pt(II) complex using spectroscopic and theoretical approaches: human hemoglobin as a target. |
| Q37276239 | Promotion of DNA strand breaks, interstrand cross-links and apoptotic cell death in A2780 human ovarian cancer cells by transplatinum planar amine complexes |
| Q50213472 | Prophage induction and mutagenecity of a series of anti-tumour platinum(II) and platinum(IV) co-ordination complexes |
| Q69405199 | Protection against cisplatin nephrotoxicity by prochlorperazine |
| Q58911169 | Pt(II) Complexes with Linear Diamines—Part I: Vibrational Study of Pt-Diaminopropane |
| Q57599961 | Pt(II) complexes of amino acids and peptides II. Structural analysis of trans-[Cl2-Pt-(H-Aib-OH)2n] and trans-[Pt-(H-Aib-O−)2] |
| Q51931934 | Pt-bridges in various single-strand and double-helix DNA sequences. DFT and MP2 study of the cisplatin coordination with guanine, adenine, and cytosine. |
| Q38760811 | Pyrithione-based ruthenium complexes as inhibitors of aldo-keto reductase 1C enzymes and anticancer agents |
| Q58486657 | QM/MM description of platinum–DNA interactions: comparison of binding and DNA distortion of five drugs |
| Q45934645 | QM/MM investigation into binding of square-planar platinum complexes to DNA fragments. |
| Q51141636 | Quantitative analysis of the flexibility effect of cisplatin on circular DNA. |
| Q46326842 | Quantitative subcellular distribution of platinum in rat tissues following i.v. bolus and i.v. infusion of cisplatin |
| Q39827612 | Radiation and platinum drug interaction |
| Q37628986 | Radio-frequency plasma polymerized biodegradable carrier for in vivo release of cis-platinum |
| Q41572976 | Reaction of cis-diamminedichloroplatinum (II) and DNA in B or Z conformation |
| Q38002872 | Reactions and structural characterization of gold(III) complexes with amino acids, peptides and proteins. |
| Q40472204 | Reactions of the UVRABC excision nuclease with DNA damaged by diamminedichloroplatinum(II). |
| Q39689828 | Rearrangement of a 1,3-trans-[Pt(NH3)2[(GXG)-N7G,N7G]] intrastrand cross-link into interstrand cross-links within RNA duplexes |
| Q97646049 | Recent Advances of Gold Compounds in Anticancer Immunity |
| Q53139745 | Recent Developments in the Medicinal Applications of Silver-NHC Complexes and Imidazolium Salts. |
| Q101578696 | Recent advances in the discovery of multi-targeted tyrosine kinase inhibitors as anticancer agents |
| Q34282236 | Recognition of cisplatin adducts by cellular proteins |
| Q39304159 | Reduced Newcastle disease virus-induced oncolysis in a subpopulation of cisplatin-resistant MCF7 cells is associated with survivin stabilization |
| Q47830147 | Reduction Process of Tetraplatin in the Presence of Deoxyguanosine Monophosphate (dGMP): A Computational DFT Study. |
| Q89870493 | Regulation and New Treatment Strategies in Breast Cancer |
| Q91949964 | Relations between approved platinum drugs and non-coding RNAs in mesothelioma |
| Q40168599 | Relationships between functionality and genetic toxicology of selected DNA-damaging agents |
| Q40783611 | Relative efficiencies of a series of square-planar platinum(II) compounds on Salmonella mutagenesis |
| Q72711040 | Renal immunolocalization of kallikrein in cisplatin nephrotoxicity in rats |
| Q71808266 | Renal insufficiency induced by cisplatin in rats is ameliorated by cyclosporin A |
| Q48321401 | Renal toxicity and chemotherapy in children with cancer. |
| Q73186773 | Renal toxicity caused by cisplatinum in glutathione-depleted metallothionein-null mice |
| Q40308378 | Renaturation effects of cis and trans platinum II and IV compounds on calf thymus deoxyribonucleic acid |
| Q36364916 | Repair of cis-platinum-DNA adducts by ABC excinuclease in vivo and in vitro |
| Q38984857 | Repurposing platinum-based chemotherapies for multi-modal treatment of glioblastoma |
| Q36458492 | Response of murine erythroleukemia cells to cis- and trans-diamminedichloroplatinum (II). |
| Q41488608 | Response of two strains of L5178Y cells to cis-dichlorobis-(cyclopentylamine)platinum(II). I. cross-sensitivity to cis-PAD and UV light |
| Q33781389 | Rho kinase inhibitor Y-27632 facilitates recovery from experimental peripheral neuropathy induced by anti-cancer drug cisplatin |
| Q34671630 | Rhodium and its compounds as potential agents in cancer treatment |
| Q38690083 | Rhodium complexes as therapeutic agents |
| Q39095650 | Robust structure and reactivity of aqueous arsenous acid-platinum(II) anticancer complexes |
| Q37230238 | Role of oxaliplatin in the treatment of colorectal cancer |
| Q33811929 | Role of p53 in the ability of 1,2-diaminocyclohexane-diacetato-dichloro-Pt(IV) to circumvent cisplatin resistance |
| Q42834264 | Ruthenium(II) [3 + 2 + 1] mixed ligand complexes: substituent effect on photolability, photooxidation of bases, photocytotoxicity and photonuclease activity |
| Q70545681 | Scandium, Chromium(VI), Gallium, Yttrium, Rhodium, Palladium, Indium in Mice: Effects on Growth and Life Span |
| Q55006915 | Self-Assembly of a [1 + 1] Ionic Hexagonal Macrocycle and Its Antiproliferative Activity. |
| Q39257995 | Self-assembled metalla-rectangles bearing azodipyridyl ligands: synthesis, characterization and antitumor activity |
| Q60585078 | Separation of platinated derivatives of nucleic acid bases on Sephadex G10 |
| Q72683670 | Severe exfoliative dermatitis associated with hand ischemia during cisplatin therapy |
| Q35688494 | Similar binding of the carcinostatic drugs cis-[Pt[NH3)2] and [Ru(NH3)5Cl] Cl2to tRNApheand a comparison with the binding of the inactivetrans-[Pt(NH3)2Cl2] complex - reluctance in binding to Watson-Crick base pain within doable helix |
| Q41718006 | Single nucleotide polymorphisms of nucleotide excision repair pathway are significantly associated with outcomes of platinum-based chemotherapy in lung cancer |
| Q47411821 | Solvent and Copper Ion-Induced Synthesis of Pyridyl-Pyrazole-3-One Derivatives: Crystal Structure, Cytotoxicity |
| Q70249798 | Some effects of combination chemotherapy with cis-platinum on renal function in patients with nonseminomatous testicular carcinoma |
| Q53364302 | Sonochemical Synthesis and Characterization of the Copper(II) Nanocomplex: DNA- and BSA-Binding, Cell Imaging, and Cytotoxicity Against the Human Carcinoma Cell Lines. |
| Q35864802 | Special Agents Hunting Down Women Silent Killer: The Emerging Role of the p38α Kinase |
| Q48264159 | Special issue: practical applications of metal complexes. |
| Q77916486 | Spectroscopic evidence for cis-[PtCl(2)(NH(3))(2)]-erythrocyte membrane interaction |
| Q30398128 | Spectroscopic investigation of Bovine Liver Catalase interactions with a novel phen-imidazole derivative of platinum. |
| Q58242834 | Stimuli-responsive Pd2L4metallosupramolecular cages: towards targeted cisplatin drug delivery |
| Q64116999 | Store-Operated Calcium Entry Contributes to Cisplatin-Induced Cell Death in Non-Small Cell Lung Carcinoma |
| Q27678705 | Structural basis of human DNA polymerase η-mediated chemoresistance to cisplatin. |
| Q38710830 | Structurally related hydrazone-based metal complexes with different antitumor activities variably induce apoptotic cell death |
| Q38797478 | Structure Effect of Some New Anticancer Pt(II) Complexes of Amino Acid Derivatives with Small Branched or Linear Hydrocarbon Chains on Their DNA Interaction |
| Q67242450 | Structure and activity relationships of platinum complexes with anti-tumour activity |
| Q27662176 | Structure of duplex DNA containing the cisplatin 1,2-{Pt(NH3)2}2+-d(GpG) cross-link at 1.77Å resolution |
| Q38740869 | Structure, function and carcinogenicity of metabolites of methylated and non-methylated polycyclic aromatic hydrocarbons: a comprehensive review |
| Q39485992 | Structure-activity relationships for organometallic osmium arene phenylazopyridine complexes with potent anticancer activity |
| Q49687144 | Structure-activity relationships for ruthenium and osmium anticancer agents - towards clinical development. |
| Q40544638 | Studies on cis-dichlorodiammineplatinum (II) as a radiosensitizer |
| Q39428358 | Study of the anticancer properties of tin(IV) carboxylate complexes on a panel of human tumor cell lines |
| Q30723906 | Study of the coordination of amino acids with metals using [trans-en2Os(eta2-H2)L]2+ as a 1H NMR probe |
| Q32103947 | Study of the interaction of DNA with cisplatin and other Pd(II) and Pt(II) complexes by atomic force microscopy |
| Q44025748 | Study on the amount of binding of anti-tumor metal complexes to different target sites of dGMP using trans-[en(2)Os(eta2-H(2))(CF(3)SO(3))](CF(3)SO(3)) in a competitive mode |
| Q45180822 | Study on the interaction between a water-soluble dinuclear nickel complex and bovine serum albumin by spectroscopic techniques |
| Q38833511 | Sugar-boronate ester scaffold tethered pyridyl-imine palladium(II) complexes: synthesis and their in vitro anticancer evaluation. |
| Q40728629 | Suppression of spleen lymphocyte mitogenesis in mice injected with platinum compounds |
| Q53944459 | Survival and SOS induction in cisplatin-treated Escherichia coli deficient in Pol II, RecBCD and RecFOR functions. |
| Q69270075 | Synergistic antitumor activity of cisplatin and UFT in nude mice bearing transplantable nasopharyngeal hybridoma |
| Q38990462 | Syntheses and structural investigation of some alkali metal ion-mediated LV(V)O2(-) (L(2-) = tridentate ONO ligands) species: DNA binding, photo-induced DNA cleavage and cytotoxic activities |
| Q58385411 | Syntheses, Characterization, and Antitumor Activities of Platinum(II) and Palladium(II) Complexes with Sugar-Conjugated Triazole Ligands |
| Q42141944 | Synthesis and Antiproliferative Activity of Steroidal Thiosemicarbazone Platinum (Pt(II)) Complexes |
| Q63247947 | Synthesis and Evaluation of the Antiproliferative Properties of a Tethered Tubercidin-Platinum(II) Complex |
| Q44616689 | Synthesis and Physicochemical, Antimitogenic, and Antiviral Properties of a Novel Palladium (II) Coordination Compound |
| Q38928386 | Synthesis and anticancer activities of a novel class of mono- and di-metallic Pt(II)(salicylaldiminato)(DMSO or Picolino)Cl complexes. |
| Q30358389 | Synthesis and anticancer activity of carbosilane metallodendrimers based on arene ruthenium(ii) complexes |
| Q41879977 | Synthesis and antitumor activity of a series of (aminoethylpyrrolidine) platinum complexes |
| Q32121495 | Synthesis and antitumour activity of platinum(II) and platinum(IV) complexes containing ethylenediamine-derived ligands having alcohol, carboxylic acid and acetate substituents. Crystal and molecular structure of [PtL4CL2].H20 where L4 is ethylenedi |
| Q39137763 | Synthesis and crystal structure of binuclear copper(II) complex bridged by N-(2-hydroxyphenyl)-N'-[3-(diethylamino)propyl]oxamide: in vitro anticancer activity and reactivity toward DNA and protein |
| Q38561236 | Synthesis and cytotoxic activity of dextran carrying cis-dichloro(cyclohexane-trans-l-1,2-diamine)platinum(II) complex |
| Q40246525 | Synthesis and cytotoxicity of enantiomerically pure [1,2-diamino-1-(4-fluorophenyl)-3-methylbutane]platinum(II) complexes |
| Q42461721 | Synthesis and pharmacological evaluation of modified adenosines joined to mono-functional platinum moieties. |
| Q94089335 | Synthesis of Platinum Complexes from N-Benzyl-1,3-Propane-diamine Derivatives, Potential Antineoplastic Agents |
| Q39162262 | Synthesis of antitumor azolato-bridged dinuclear platinum(ii) complexes with in vivo antitumor efficacy and unique in vitro cytotoxicity profiles |
| Q86838174 | Synthesis of enantiomeric pureCis-dichloroplatinum(II) amino acid complexes |
| Q67872690 | Synthesis, Antitumor Activity, and Nephrotoxicity of the Optical Isomers of 2-Aminomethylpyrrolidine(1,1-cyclobutane-dicarboxylato)platinum(II) |
| Q38716555 | Synthesis, Biological Evaluation, and Molecular Docking Studies on the DNA Binding Interactions of Platinum(II) Rollover Complexes Containing Phosphorus Donor Ligands. |
| Q41865609 | Synthesis, Characterization, and Cytotoxicity of the First Oxaliplatin Pt(IV) Derivative Having a TSPO Ligand in the Axial Position. |
| Q59172597 | Synthesis, Characterization, and In Vitro Antitumor Activity of New Amidineplatinum(II) Complexes Obtained by Addition of Ammonia to Coordinated Acetonitrile |
| Q30607784 | Synthesis, Characterization, and Interaction with Biomolecules of Platinum(II) Complexes with Shikimic Acid-Based Ligands |
| Q59867933 | Synthesis, Cytotoxicity and Antibacterial Studies of Novel Symmetrically and Nonsymmetrically 4-(Methoxycarbonyl)benzyl-Substituted N-Heterocyclic Carbene-Silver Acetate Complexes |
| Q38904045 | Synthesis, X-ray structure and in vitro cytotoxicity studies of Cu(I/II) complexes of thiosemicarbazone: special emphasis on their interactions with DNA. |
| Q44378286 | Synthesis, characterization and antitumor activity of novel octahedral Pt(IV) complexes |
| Q91787414 | Synthesis, characterization and biological activities of imidazo[1,2-a]pyridine based gold(III) metal complexes |
| Q31011200 | Synthesis, characterization and biological activity of trans-platinum(II) and trans-platinum(IV) complexes with 4-hydroxymethylpyridine. |
| Q35803993 | Synthesis, characterization and biological activity of trans-platinum(II) complexes with chloroquine |
| Q57843316 | Synthesis, characterization and biomolecule-binding properties of novel tetra-platinum(ii)-thiopyridylporphyrins |
| Q34396926 | Synthesis, characterization, DNA binding and cleavage, BSA interaction and anticancer activity of dinuclear zinc complexes |
| Q31056225 | Synthesis, characterization, DNA binding, cleavage activity, cytotoxicity and molecular docking of new nano water-soluble [M(5-CH₂PPh₃-3,4-salpyr)](ClO₄)₂ (M = Ni, Zn) complexes. |
| Q36270717 | Synthesis, characterization, and evaluation of cis-diphenyl pyridineamine platinum(II) complexes as potential anti-breast cancer agents |
| Q39465410 | Synthesis, characterization, and in vitro antitumor properties of gold(III) compounds with the traditional Chinese medicine (TCM) active ingredient liriodenine |
| Q39293908 | Synthesis, characterization, cellular uptake, apoptosis, cytotoxicity, dna-binding, and antioxidant activity studies of ruthenium(II) complexes |
| Q86002412 | Synthesis, crystal structure, and biological activities of two chiral mononuclear Mn((III)) complexes |
| Q87383865 | Synthesis, cytotoxicity, induction of apoptosis, and interaction with DNA of dinuclear platinum(II) complexes |
| Q34933612 | Synthesis, photophysics, and reverse saturable absorption of platinum complexes bearing extended π-conjugated C^N^N ligands |
| Q37722632 | Synthetic methods for the preparation of platinum anticancer complexes |
| Q26863585 | Systems biology of cisplatin resistance: past, present and future |
| Q41908532 | TWIST interacts with endothelin-1/endothelin A receptor signaling in osteosarcoma cell survival against cisplatin |
| Q39217966 | TWIST interacts with β-catenin signaling on osteosarcoma cell survival against cisplatin |
| Q43122076 | Targeted Chemotherapy with Metal Complexes |
| Q34550075 | Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo |
| Q36970889 | Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles |
| Q36877212 | Targeted single-wall carbon nanotube-mediated Pt(IV) prodrug delivery using folate as a homing device |
| Q39775092 | Tautomeric forms study of 1H-(2'-pyridyl)-3-methyl-5-hydroxypyrazole and 1H-(2'-pyridyl)-3-phenyl-5-hydroxypyrazole. Synthesis, structure, and cytotoxic activity of their complexes with palladium(II) ions |
| Q37523040 | Testicular Germ Cell Tumors: A Paradigm for the Successful Treatment of Solid Tumor Stem Cells |
| Q35116876 | The Chemical and Biological Effects of cis -Dichlorodiammineplatinum (II), an Antitumor Agent, on DNA |
| Q39798817 | The Crystal Structures of Metal Complexes of Nucleic Acids and Their Constituent |
| Q41150062 | The Mechanism of Action of Antitumor Platinum Compounds |
| Q91786131 | The Melding of Drug Screening Platforms for Melanoma |
| Q28066801 | The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs |
| Q54364011 | The anticancer drug, cisplatin, increases the naturally occurring cell-mediated lysis of tumor cells. |
| Q41579853 | The antitumor activity of the platinum complex D-17872 is associated with tumor cell differentiation |
| Q73714919 | The cellular distribution and oxidation state of platinum(II) and platinum(IV) antitumour complexes in cancer cells |
| Q55980246 | The detection of trace amounts of trans-Pt(NH3)2Cl2 in the presence of cis-Pt(NH3)2Cl2. A high performance liquid chromatographic application of kurnakow's test |
| Q77891517 | The effect of a Titanocene Dichloride derivative, Ti IV (C5H5)(2) NCS(2), on the haematopoietic response of Ehrlich tumour-bearing mice |
| Q54761524 | The effect of cis-dichlorodiammineplatinum(II) on Escherichia coli B the role of fil, exr and hcr markers |
| Q77923864 | The effect of cobalt chloride on serum protein electrophoretic patterns in mice |
| Q36068602 | The effect of combined treatment with a platinum complex and ionizing radiation on chinese hamster ovary cells in vitro |
| Q39929512 | The effect of heavy metal chelators on the renal accumulation of platinum after cis-dichlorodiammineplatinum II administration to the rat. |
| Q37171242 | The effect of ligand lipophilicity on the nanoparticle encapsulation of Pt(IV) prodrugs |
| Q38842569 | The effect of potential supramolecular-bond promoters on the DNA-interacting abilities of copper-terpyridine compounds |
| Q51765470 | The effects of anaesthetics on cisplatinum-induced toxicity at normal temperatures and during whole-body hyperthermia: the influence of NaCl concentration of the vehicle. |
| Q70039601 | The effects of cisplatin on rat spinal ganglia: a study by light and electron microscopy and by morphometry |
| Q39698183 | The effects of platinum complexes on seven enzymes |
| Q52931757 | The gas-phase chemistry of cis-diammineplatinum(II) complexes: a joint experimental and theoretical study. |
| Q39737590 | The in vivo inhibition of tumor growth by ruthenium red: its relationship with the metabolism of calcium in the tumor |
| Q44594192 | The interaction of platinum II compounds with bacteriophages T7 and R17 |
| Q43624407 | The interaction of radiation and cis-diamminedichloroplatinum (II) in intestinal crypt cells |
| Q92100267 | The interaction of silver(II) complexes with biological macromolecules and antioxidants |
| Q51624154 | The interactions of cisplatin and DNA studied by atomic force microscopy |
| Q40943542 | The kinetics and cytotoxicity of cisplatin and its monohydrated complex |
| Q52527114 | The mutagenic effect of platinum compounds in Drosophila melanogaster. |
| Q34474051 | The phosphate clamp: a small and independent motif for nucleic acid backbone recognition |
| Q27729148 | The primary mode of binding of cisplatin to a B-DNA dodecamer: C-G-C-G-A-A-T-T-C-G-C-G |
| Q40532517 | The reaction of platinum(II) complexes with DNA. Kinetics of intrastrand crosslink formation in vitro |
| Q34649255 | The resurgence of platinum-based cancer chemotherapy |
| Q48157721 | The role of arsenic in the hydrolysis and DNA metalation processes in an arsenous acid-platinum(ii) anticancer complex |
| Q20906133 | The therapeutic potential of metal-based antimalarial agents: implications for the mechanism of action |
| Q54482434 | The tumor-inhibiting effect of isomeric dichloro(diphenylethylenediamine)platinum(II) complexes. |
| Q46336845 | The π-acceptor effect in the substitution reactions of tridentate N-donor ligand complexes of platinum(II): a detailed kinetic and mechanistic study |
| Q90268304 | Theranostic Lysosomal Targeting Anticancer and Antimetastatic Agents: Half-Sandwich Iridium(III) Rhodamine Complexes |
| Q104284185 | Theranostics through the synergistic cooperation of heterometallic complexes |
| Q38431547 | Therapeutic applications of spherical nucleic acids |
| Q38292983 | Therapeutic gold, silver, and platinum nanoparticles |
| Q40153857 | Therapeutic progress--review VIII. Do the newer cytotoxic drugs represent a significant advance in the treatment of cancer? |
| Q34063391 | Thermodynamic and kinetic behaviour of [Pt(2-methylthiomethylpyridine)(OH2)2]2+. |
| Q39933300 | Timed‐Release Depot for Anticancer Agents |
| Q61805438 | Tissue-Specific Chk1 Activation Determines Apoptosis by Regulating the Balance of p53 and p21 |
| Q34671639 | Titanium complexes in cancer treatment |
| Q39611571 | Titanocene anticancer complexes and their binding mode of action to human serum albumin: a computational study |
| Q44020716 | Topoisomerase II antagonism and anticancer activity of coordinated derivatives of [RuCl(2)(C(6)H(6))(dmso)]. |
| Q52248411 | Toxicity and antitumor activity of cis-bis-carboxylato(trans-R,R-1,2-diaminocyclohexane) platinum(II) complexes entrapped in liposomes. |
| Q39184839 | Transition metal complexes with oligopeptides: single crystals and crystal structures |
| Q98178472 | Triggering of Apoptosis in Osteosarcoma 143B Cell Line by Carbon Quantum Dots via the Mitochondrial Apoptotic Signal Pathway |
| Q33797148 | Ultrastructure of Chlamydomonas eugametos palmelloids induced by chloroplatinic acid treatment |
| Q34396623 | Understanding and improving platinum anticancer drugs--phenanthriplatin |
| Q69884769 | Unexpected mobilisation of lead during cisplatin chemotherapy |
| Q37868960 | Unique platinum-DNA interactions may lead to more effective platinum-based antitumor drugs |
| Q40954510 | Urinary TIMP2⋅IGFBP7 for the prediction of platinum-induced acute renal injury. |
| Q35317195 | Use of the comet assay technique for quick and reliable prediction of in vitro response to chemotherapeutics in breast and colon cancer. |
| Q34132691 | Using synthetic DNA interstrand crosslinks to elucidate repair pathways and identify new therapeutic targets for cancer chemotherapy |
| Q37026980 | Visualizing inhibition of nucleosome mobility and transcription by cisplatin-DNA interstrand crosslinks in live mammalian cells |
| Q40791052 | WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach |
| Q39000939 | Water-soluble DNA minor groove binders as potential chemotherapeutic agents: synthesis, characterization, DNA binding and cleavage, antioxidation, cytotoxicity and HSA interactions |
| Q39768981 | Water-soluble organometallic analogues of oxaliplatin with cytotoxic and anticlonogenic activity |
| Q67313471 | X-ray photoelectron spectroscopy of DNA · Pt complexes Evidence of O6(Gua) · N7(Gua) chelation of DNA with cis-dichlorodiamine platinum(II) |
| Q42246601 | [Biological effects of coordination compounds of transitional metals. The beta-lactamase inhibitory effect of cis-platin, 2-aminopyridine palladium chloride, clavulanic acid and penicillanic acid sulfonate CP 45,899 in the nitrocefin test and Titert |
| Q54134785 | [Cytostatic non-platinum metal complexes: new perspectives for the treatment of cancer?]. |
| Q69576604 | [Cytostatic platinum complexes: an unexpected discovery with considerable consequences] |
| Q73664263 | [Transient electrical birefringence study of the interaction between DNA and platinum compounds: cis-DDP, trans-DDP and TDP] |
| Q70646077 | [Tumor inhibition by metallocenes: effect of titanocene, zirconocene, and hafnocene dichlorides on Ehrlich ascites tumor in mice (author's transl)] |
| Q39805147 | cis-Diamminedichloroplatinum (II): A Metal Complex with Significant Anticancer Activity |
| Q36785141 | cis-Dichlorodiammineplatinum(II): cytological changes induced in Escherichia coli |
| Q41625727 | cis-Platinum in advanced gynecologic malignancy |
| Q50619101 | cis-Platinum ototoxicity. |
| Q50095469 | cis-Platinum pro-drug-attached CuFeS2 nanoplates for in vivo photothermal/photoacoustic imaging and chemotherapy/photothermal therapy of cancer. |
| Q44080713 | cis-dichlorodiammineplatinum(II): Hematopoietic effects in rats |
| Q36073424 | hsDNA groove binding, photocatalytic activity, and in vitro breast and colon cancer cell reducing function of greener SeNPs |
| Q37681865 | miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST. |
| Q39342904 | miR-34a is downregulated in cis-diamminedichloroplatinum treated sinonasal squamous cell carcinoma patients with poor prognosis. |
| Q42538506 | miR-96 induces cisplatin chemoresistance in non-small cell lung cancer cells by downregulating SAMD9. |
| Q64033092 | β-Diketones as Scaffolds for Anticancer Drug Design - From Organic Building Blocks to Natural Products and Metallodrug Components |
Search more.